ClinicalTrials.gg

Program

nor-ursodeoxycholic acid

Also written as “norucholic acid”, “norUrsodeoxycholic Acid” and “norUrsodeoxycholic acid”.

Its studies are mostly in Cholangitis, Sclerosing · Non-alcoholic Fatty Liver Disease, led by Dr. Falk Pharma.

Furthest: phase 3, since Mar 8, 20193 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. Falk Pharma33 open or runningphase 3since Mar 8, 2019Mar 8, 2019Sep 2027phase 3 · NCT06886360

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2019First study: phase 3 study in Cholangitis, SclerosingFirst studyNCT03872921 · 303 enrolled · Austria, Germany
  2. Oct 6, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05083390 · 363 planned · Austria
  3. Mar 14, 2025Phase 3 study in Cholangitis, SclerosingNCT06886360 · 120 planned

Ahead

  1. Sep 2027Primary completion: phase 3 study in Cholangitis, SclerosingNCT06886360

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06886360Cholangitis, Sclerosing3Not yet recruitingSep 2027120
NCT05083390Non-alcoholic Fatty Liver Disease · Austria2RecruitingJan 2025363
NCT03872921Cholangitis, Sclerosing · Austria, Germany3Active, not recruitingJan 2025303

How it is read

Names in the registry

  • “norucholic acid”, 1 entry
  • “norUrsodeoxycholic Acid”, 1 entry
  • “norUrsodeoxycholic acid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.